Previous 10 | Next 10 |
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:0...
2023-10-09 13:48:03 ET Summary Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been ...
2023-10-06 07:35:00 ET Summary Charlie Munger passively made a fortune with his $1,000 oil royalty investment in 1962. Royalty interests are an unstoppable force for inflation-beating passive income. Each royalty firm has a unique treasure chest waiting to be unlocked. Joi...
2023-09-27 16:04:37 ET Morgan Stanley in its 2023 Dividend Playbook on Wednesday selected its top stock picks for high dividend-paying industries, chosen by its bottom-up analysts. These are stocks that combine yield, growth, and stability measures and look attractive on a three to five...
2023-09-27 02:15:43 ET Summary Royalty Pharma offers a unique exposure in the pharmaceutical sector thanks to a diversified portfolio and lower operational risk vs. competitors. The Vertex franchise is a significant contributor to Royalty Pharma's earnings and this ongoing risk ap...
2023-09-21 08:39:37 ET More on Royalty Pharma Seeking Alpha’s Quant Rating on Royalty Pharma Historical earnings data for Royalty Pharma Dividend scorecard for Royalty Pharma Financial information for Royalty Pharma Royalty Pharma: We Continue ...
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk...
2023-09-18 07:27:39 ET More on IPOs Klaviyo expected to raise IPO target to $557M - report Instacart boosts IPO range to $28-$30 a share, to raise as much as $660M Arm Holdings jumps 25% in market debut for a valuation of $68B For further details see: As ...
2023-09-08 00:03:09 ET Summary The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. ...
2023-09-05 23:24:03 ET Summary Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnership with Ferring Pharmaceuticals, investing $300 million upfront for royalties on bladder cancer drug...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...